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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
epigallocatechin gallate (EGCG) improves mood in healthy adults. 
 
STUDY DESIGN: A review of three peer-reviewed journal articles written in the English 
language published between 2009 and 2012. 
 
DATA SOURCES: Three randomized, double-blind, placebo-controlled studies comparing the 
effect of EGCG to placebo on mood were found using PubMed and Cochrane databases. 
 
OUTCOMES MEASURED: Outcomes measured in the studies included change in mood. 
Patient ratings of mood were measured using Mood Visual Analog Scales (Mood VAS), the 
University of Wales Institute of Science and Technology (UWIST) mood adjective checklist, and 
the Bond-Lader mood scale. 
 
RESULTS: Wightman et al.
1
 showed no significant correlation between EGCG consumption 
and mood. Scholey et al.
2
, on the other hand, found EGCG’s effect on mood to be significant, 
increasing calmness and reducing stress with p-values of 0.04 and 0.017 respectively. Brown et 
al.
3
 achieved similar findings with a significant increase in hedonic tone (p = 0.048), although 
decrease in tense arousal did not reach statistical significance (p = 0.056). 
 
CONCLUSIONS: The summative results of these investigations indicate the need for additional 
studies examining the effects of EGCG on mood. The conflicting evidence provided by 
Wightman et al.
1
, Scholey et al.
2
, and Brown et al.
3
 leaves the question of EGCG’s efficacy in 
improving mood in healthy adults largely unanswered. Due to its relative safety, availability, and 
cost-effectiveness, further studies on efficacy of EGCG in improving mood are warranted. 
 
KEY WORDS: epigallocatechin gallate; mood 
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INTRODUCTION 
 Mood is an omniprevalent, sustained, internally-experienced feeling tone that affects our 
actions and how we perceive the world. In healthy individuals, an extensive range of moods are 
experienced daily, varying from normal to elevated to depressed and the many shades in 
between. Healthy individuals feel in control of their moods. Mood disorders occur when that 
sense of control over mood is lost and a subjective experience of distress results. Disorders of 
mood manifest in a variety of ways, but almost all who suffer from mood disorders experience a 
disturbance in interpersonal, societal, and occupational functioning.
4
 Similarly, all individuals 
experience anxiety and stress during their lifetime. These emotions, while often completely 
healthy and at times even beneficial, may become pathologic if they are uncontrolled, cause 
psychological distress, and interfere in other aspects of the individual’s life.5 
 An exact number of health care visits per year allocated to mood remains unknown. 
However, a 2012 estimate indicates that 1,035,537 patients were seen for mental health related 
visits.
6
 Depression, one of the most prevalent mood disorders, is a leading cause of morbidity 
and mortality, and its treatment accounts for a large portion of physician-prescribed medications. 
Estimates designate it the second leading cause of disability worldwide.
7
 Similarly, anxiety 
disorders affect about 30 million people in the United States and are associated with significant 
morbidity.
5
 Anxiety and mood disorders are extremely prevalent entities and account for a large 
number of mental health diagnoses.
4,5
  In 2007, approximately 26.8 million adults age 18 or older 
reported receiving treatment for anxiety and mood disorders.
8
 A total of $36.8 billion was spent 
on treating these conditions, half of which was on prescription medications.
8
 In the same year, 
$1,374 per adult per year was spent by those with anxiety and mood disorder related expenses. 
8
 
 The exact physiology of normal mood regulation as well as the pathophysiology of mood 
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disorders remains largely unknown. Some evidence suggests that regulation of monoamine 
neurotransmitters may be involved, specifically serotonin and norepinephrine.
7
 Major mood 
disorders are thought to involve various etiologies including genetics, environmental stress, 
dysregulation of neurotransmission, abnormal neuroplasticity, and altered gene expression.
9
 
According to the Sequenced Treatment Alternatives to Relieve Depression (STAR’D) trial, 
current antidepressant treatments do not provide high remission rates for depression.
9
 Similarly, 
anxiety disorders are often chronic and resistant to treatment.
5
 
 Current pharmacotherapy for mood and anxiety disorders includes selective serotonin 
reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), atypical 
antidepressants, tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and 
benzodiazepines. Other potential therapies include psychotherapy such as cognitive and 
behavioral therapy, and electroconvulsive therapy (ECT).
5,7
 While the SSRIs, SNRIs, and 
atypical antidepressants have improved side effect profiles over the older MAOIs and TCAs, 
they have not shown increased efficacy in treatment of mood disorders.
9
 Benzodiazepines are 
most commonly used for treatment of anxiety disorders. While the majority of those with anxiety 
disorders benefit from such pharmacotherapy initially, up to 80% of individuals relapse within a 
year of discontinuing the medication.
5
 Currently, psychotherapy and ECT are used adjunctively 
or as alternatives to pharmacologic treatment. While the various psychotherapies have shown 
equal efficacy to that of pharmacotherapy alone, evidence remains conflicting whether there is 
increased benefit to combination pharmacologic and psychotherapy. Nevertheless, some studies 
do suggest improved outcomes with a combination of therapeutic disciplines.
4
 ECT is typically 
only considered in resistant, severely debilitating cases.
5
 Regardless of the therapeutic methods 
used, there remains room for improvement in treatment of anxiety and mood disorders not only 
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to increase therapeutic efficacy, but also to decrease side effects and reduce cost. 
 Tea, derived from the plant Camellia sinensis, remains one of the most commonly 
consumed beverages across the world.
3
 Epigallocatechin gallate (EGCG), a natural flavonoid in 
green tea, has been linked to a variety of health benefits including weight management and 
prevention of chronic conditions such as cardiovascular disease, cancer, and neurodegenerative 
conditions. Some evidence suggests a significant association between green tea and decreased 
psychological distress.
2
 In addition, green tea has been linked to anxiolytic activity and has been 
proposed to exhibit relaxation properties. Consumption of green tea and specifically EGCG, have 
therefore been hypothesized to have positive effects on individuals’ self-reported mood.3 
Disturbances in mood, whether temporary or prolonged, physiologic or pathologic, can 
affect all aspects of an individual’s life. As a result, enhancing our understanding of mood 
physiology and investigating mechanisms for improving mood may serve an important role in 
augmenting quality of life. Finding new ways to enhance mood, even physiologic changes in 
mood, may be beneficial for all individuals seeking an increased quality of life. Therefore, this 
paper evaluates three double blind, randomized controlled trials comparing the efficacy of 
epigallocatechin gallate to placebo on improving mood. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not 
epigallocatechin gallate improves mood in healthy adults. 
METHODS 
 Three double blind, randomized controlled trials were included in this systematic review. 
Studies were selected based on various criteria including population studied, interventions used, 
comparisons made, and outcomes measured. In all three studies, the population consisted of 
 Wong ǀ Epigallocatechin Gallate and Mood 4 
 
healthy adults over 18 years of age. Brown et al.
3
 included only male nonsmokers between 40 
and 65 while Scholey et al.
2
 and Wightman et al.
1
 included both males and females ages 18 to 37 
and 18 to 30 respectively. The intervention applied was epigallocatechin gallate (EGCG). Brown 
et al.
3
 gave 400 mg EGCG BID in the form of Teavigo, a purified green tea extract with > 97% 
EGCG content. Scholey et al.
2
 also gave Teavigo, but used 300 mg capsules with 94% EGCG 
content. Wightman et al.
1
 had two treatment groups, giving either 135 or 270 mg EGCG capsules 
with 94% EGCG content. In all three studies, EGCG effects were compared to those of placebo. 
Scholey et al.
2
 used flour capsules whereas Brown et al.
3
 used 400 mg lactose as the control.
2,3
 
Selected studies were randomized, double blind, placebo-controlled trials comparing the effects 
of EGCG to placebo on mood and included change in mood as a measured outcome. 
 Articles were researched via PubMed and Cochrane databases and were selected based on 
relevance to the clinical question and that measured outcomes included patient oriented evidence 
that matters (POEMS). Key words entered in the PubMed search included “epigallocatechin 
gallate” and “mood.” All three of the selected studies were peer-reviewed journal articles written 
in the English language published between 2009 and 2012. 
Studies included in this systematic review were selected based on the following inclusion 
criteria: all were primary research studies, randomized controlled trials, published after 1996, 
included POEMS, and evaluated change in mood as one of the measured outcomes. Exclusion 
criteria included studies involving those under 18 years of age or diagnosed with a significant 
medical condition including but not limited to diabetes mellitus, neurological or psychological 
disorder, food allergy or metabolism disorder, drug abuse, or tobacco use. Statistics reported in 
the three studies include the paired t-test, p-value, mean change from baseline, and ANCOVA. 
See Table 1 below for Demographics and Characteristics of Included Studies. 
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Table 1: Demographics & Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Brown, 
2009
3
 
Double 
blind 
RCT 
100 40-65 Male, 
nonsmokers, 
40-65 years 
old, BMI > 28 
and < 38 
kg/m
2
, fasting 
plasma 
glucose < 7.0 
mmol/l 
Significant history 
of disease, current 
disease, or on 
medication 
12 400 mg EGCG 
BID (Teavigo) 
vs placebo 
(400 mg 
lactose) BID 
Scholey, 
2011
2
 
Double 
blind 
RCT 
31 Mean 
27.74, 
SD 
9.28 
Nonsmokers, 
normal weight 
(mean 71.4 
kg, range 46-
95), right-
handed, 
English 
speaking 
Taking illicit drugs, 
medications, or 
natural therapies, 
psychological 
(depression, 
anxiety) or physical 
conditions (food 
allergies, kidney, 
liver, and/or 
gastrointestinal 
diseases) that 
would affect food 
metabolism 
2 300 mg EGCG 
(Teavigo) vs 
placebo 
(identical 
capsule 
containing 
flour) 
Wightman, 
2012
1
 
Double 
blind 
RCT 
27 18-30 Self-reported 
good health, 
free from 
social drugs, 
alcohol, 
prescription 
medication, 
and herbal 
extracts/food 
supplements 
Patients who had 
suffered a head 
injury, neurological 
disorder, 
neurodevelopmenta
l disorder, relevant 
food allergies or 
intolerances, 
smoked tobacco, 
drank > 600 
mg/day of caffeine, 
or took illicit social 
drugs 
5 135 mg EGCG 
vs 270 mg 
EGCG vs 
placebo 
OUTCOMES MEASURED 
 Outcomes measured for all selected studies included patient rating of mood. Various 
scales were used, each with slightly different criteria. Wightman et al.
1
 used the Mood Visual 
Analog Scale (Mood VAS) in which participants rated aspects of mood from 0-100. The Mood 
VAS included ratings of how relaxed, alert, jittery, tired, tense, and mentally fatigued subjects 
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felt in addition to an assessment of overall mood.
1
 Scholey et al.
2
 also required ratings of mood 
from 0-100, but instead used the Bond-Lader mood scale. In this trial, subjects rated level of 
alertness, calmness, contentedness, stress, and fatigue.
2
 The final study by Brown et al.
3
 assessed 
mood with the University of Wales Institute of Science and Technology mood adjective checklist 
which measured level of energetic arousal, tense arousal, hedonic tone, and general arousal.
3
 
RESULTS 
 While all three studies were double blind, randomized controlled trials evaluating a 
population of healthy adults, two of the studies included both male and female participants while 
one included only males. Similarly, although all selected studies evaluated only adults over 18 
years of age, one study utilized participants 40-65 years of age whereas the others studied those 
18-30 and 18-37 years of age.
1-3
 Since investigators were interested in purely healthy adults, 
Wightman et al.
1
 included only those participants who reported themselves in good health and 
who did not use drugs, alcohol, prescription medications, food supplements or herbal extracts 
and excluded those reporting a head injury, neurologic or neurodevelopmental disorder, relevant 
food allergies, tobacco or illicit drug use, or consumption of over 600 mg caffeine per day. 27 
healthy adults were included in the trial while an additional 5 were replaced during the trial due 
to nonadherence to testing procedures. All five were replaced before blinding was revealed.
1
 
Scholey et al.
2
 included English speaking, right-handed, non-smokers of normal weight who did 
not take illicit drugs, medications, or natural therapies, and excluded those with psychological 
disorders such as depression or anxiety and physical conditions such as food allergies, kidney, 
liver, or gastrointestinal diseases which may have affected food metabolism.
2
 Brown et al.
3
 
included only males self-reported as non-smokers with a BMI between 28 and 38 kg/m
2
 and a 
fasting plasma glucose ˂ 7.0 mmol/L. Those with significant current or past history of disease or 
 Wong ǀ Epigallocatechin Gallate and Mood 7 
 
those on medications were excluded from the study. 100 participants were selected, matched for 
age and insulin resistance, and randomized into placebo and EGCG groups. Of the 50 subjects in 
each group, 6 of those in the placebo group did not receive the allocated intervention. In the 
EGCG group, all 50 received the allocated intervention, but 1 discontinued intervention during 
the study due to starting a new medication. For analysis, 2 members of the placebo group and 3 
members of the EGCG group were excluded due to elevated 2 hour glucose values of ≥ 11.1 
mmol/L resulting in n = 42 in the placebo group and n = 46 for the EGCG intervention. 
Teavigo, the intervention in two of the studies has been confirmed safe for human use 
without any reported adverse effects.
2
 Wightman et al.
1
 makes no mention of their EGCG 
capsule safety, but no subjects were reported lost due to adverse reactions or intolerability. 
Similarly, neither Scholey et al.
2
 nor Brown et al.
3
 report discontinuation of the study due to 
adverse effects of EGCG intervention. 
Wightman et al.
1
 tested two doses of EGCG, 135 and 270 mg per day on three separate 
occasions.  The authors were unable to determine a significant difference in outcomes in those 
receiving placebo compared to either dose of EGCG. Therefore, Wightman et al.
1
 did not supply 
data analyzing effect on mood, indicating that “no significant treatment-related differences were 
observed.”1 Likewise, specific test statistics and statistics signifying precision of treatment effect 
were not reported due to lack of evidence demonstrating significant change in mood. 
 Scholey et al.
2
 examined a 300 mg dose of EGCG per day given on two separate 
occasions one week apart and found a significant difference in change from baseline with 
treatment effect. While Scholey et al.
2
 did not provide specific data for either EGCG or placebo 
groups when reporting stress and calmness, the p-values for both indicate that the difference 
between treatments was large enough to be considered statistically significant. The authors did 
 Wong ǀ Epigallocatechin Gallate and Mood 8 
 
not provide enough data for conversion to dichotomous data. Instead, they reported t-test values 
comparing group change from baseline. Results of the t-test indicated an increase in self-reported 
calmness with EGCG compared to placebo with a t-value for EGCG of 2.17 (p = 0.04).
2
 Results 
also showed a decrease in self-reported stress with an EGCG t-value of 2.52 (p = 0.017).
2
 Results 
are provided in Table 2 below. Other mood measures showed no significant difference from 
placebo and the authors therefore did not provide associated data.
2
 
Table 2: Mean Change from Baseline with EGCG Consumption 
 T-Test (n = 29) P-Value 
Calmness 2.17 0.04 
Stress 2.52 0.017 
 Brown et al.
3
 compared treatment with 800 mg EGCG per day to 800 mg placebo for 8 
weeks. The authors reported mean hedonic tone and tense arousal for both EGCG and placebo at 
baseline and post-intervention. The treatment effect appears relatively small given that the 
EGCG group’s mean hedonic tone was essentially the same pre and post intervention (29.10 and 
29.11 respectively).
3
 The difference in EGCG and placebo post-intervention hedonic tone was 
considered statistically significant, however, with a p-value of 0.048.
3
 Despite statistical 
significance, this difference appears largely due to change in placebo group between baseline and 
post-intervention (29.25 and 27.84 respectively), rather than to treatment effect.
3
 For tense 
arousal, treatment appears to have had a slightly greater effect in altering the EGCG group’s 
mean score from baseline, but post-intervention difference between placebo and EGCG did not 
reach statistical significance (p = 0.056).
3
 Energetic and general arousal measures did not reach 
statistical significance and data was therefore not provided. The authors did not provide enough 
information for conversion to dichotomous data, but did report mean post-intervention and 
baseline scores for control and treatment groups as provided in Table 3 below. They also noted 
use of a mixed model repeated measures ANCOVA to analyze the relationship between self-
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reported mood and treatment administered, while controlling for other variables inherent in the 
study’s design. Covariates included alcohol intake, diet, physical activity, and body weight 
change and were not found to significantly impact mood results. Specific data was not provided.
3
 
Table 3: Mean Values at Baseline and Post-therapy - EGCG versus Placebo 
Baseline: Hedonic Tone Tense Arousal 
     EGCG 29.10 (SD 3.68) 11.29 (SD 3.06) 
     Placebo 29.25 (SD 3.72) 11.83 (SD 3.99) 
     P-Value ≤ 0.05 ≤ 0.05 
Post-Therapy:   
     EGCG 29.11 (SE 0.44) 11.06 (SE 0.47) 
     Placebo 27.84 (SE 0.46) 12.33 (SE 0.45) 
     P-Value 0.048 0.056 
DISCUSSION 
 Conflicting evidence in the three studies included in this review presents difficulty in 
determining conclusive effects of EGCG on mood. It appears that higher doses of EGCG may 
affect some aspects of mood, but further study is warranted before definitive conclusions can be 
reached. The ability of 300 mg EGCG to increase calmness while reducing stress and 800 mg to 
significantly increase hedonic tone offers a promising outlook on the ability of EGCG to improve 
mood.
2,3
 Such evidence is tempered, though, by the inability of 135 and 270 mg to considerably 
alter mood parameters and failure of 800 mg EGCG to significantly reduce tense arousal.
1,3
 
Nonetheless, green tea, with its high EGCG content, remains one of the most widely 
consumed beverages in the world. It has long been proposed to possess health-enhancing 
properties and is generally considered safe for consumption.
10
 Green tea extracts are deemed safe 
for up to one year, and EGCG has been well tolerated at 800 mg per day for up to 4 weeks.
10, 11
 
Although not routine primary therapy, studies have found green tea extract useful in treatment of 
obesity, cancer, and high cholesterol. Currently, it is also under investigation for anxiety, stroke, 
diabetes, Alzheimer’s and Parkinson’s disease, hypertension, and osteoporosis.10,11 Regardless of 
its equivocal efficacy, green tea extracts are relatively inexpensive and may provide a more cost-
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effective approach to moderation of mood disorders than presently available pharmacotherapy.
11
 
 Currently, green tea is not recommended for infants, children, or pregnant women due to 
caffeine content. Caffeine also affects CYP450 metabolism and may therefore interact with 
SSRIs and SNRIs, both of which are commonly used to treat mood disorders. EGCG capsules, 
on the other hand, do not contain caffeine and have not shown significant interaction with 
commonly used anxiety or mood disorder medications. 
10
 Potential interactions do exist, 
however, and include increased bleeding risk with concomitant use of vitamin K antagonists, 
nonsteroidal anti-inflammatories, anticoagulants, salicylates, antiplatelets, or thrombolytics, 
depletion of folic acid levels, and increased serum concentrations of simvastatin. No adverse 
effects have been observed with daily green tea consumption. Its extracts, however, have been 
linked to hepatotoxicity, especially at high doses or if taken without food. While unproven, 
EGCG or its metabolites are suspected to be responsible. Other potential adverse effects include 
headache, dizziness, and gastrointestinal disturbances. To date, no contraindications to green tea 
extract exist, although caution is advised in those with hepatic failure.
11
 
 In this review, several factors may limit generalizability to a broader population. One 
such limitation is that green tea extract and EGCG are natural products. Dosing is therefore not 
standardized by the FDA. Depending on the manufacturer and product used, EGCG content may 
vary which could affect study outcomes.
 10 
In addition, sample sizes in all three studies were 
relatively small. Wightman et al.
1
 included only 27 participants while Scholey et al.
2
 included 31. 
Brown et al.
3
, the largest of the three, included only 100 participants in the trial. Excepting 
Wightman et al.
1
, studies did not restrict consumption of flavonoid-containing items other than 
green tea. Therefore, intake of additional substances containing EGCG or other flavonoids may 
have affected study outcomes. In Wightman et al.
1
, several subjects lost during the trial were 
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replaced before blinding was revealed. This may have inadvertently altered group randomization. 
While Wightman et al.
1
 and Scholey et al.
2
 included both males and females over 18, the upper 
limits of their age groups did not extend past 37 years old. Alternatively, Brown et al.
3
included 
only males and studied those between 40 and 65, failing to include younger adults and excluding 
female participants. In addition, Brown et al.
3
 employed subjects with some insulin resistance. 
Although still considered healthy adults, the presence of insulin resistance and exclusion of 
certain gender and age groups may limit applicability to a broader adult population. Furthermore, 
variation in administered EGCG dosage between the three studies and use of different, although 
validated, scales for mood quantification makes comparison of effects on mood difficult. 
10
 
CONCLUSION 
Overall, evidence in this review leaves the question of EGCG’s efficacy in improving 
mood in healthy adults largely unanswered. While Wightman et al.
1
 determined EGCG did not 
appreciably affect mood, Scholey et al.
2
 found EGCG to significantly increase calmness and 
reduce stress as compared to placebo. Meanwhile, Brown et al.
3
 determined EGCG to somewhat 
alter mood, significantly increasing hedonic tone compared to placebo, and although it also 
decreased tense arousal, this did not reach statistical significance. Due to conflicting data 
between studies, a definitive conclusion on EGCG efficacy in altering mood cannot be reached. 
In light of its relative safety, availability, and low cost, further study on EGCG’s efficacy 
in improving mood is warranted. While current data remains inconclusive, further research may 
elicit additional evidence on EGCG’s ability to alter mood. Prospective studies should focus on 
additional doses and standardization of EGCG content as well as assess efficacy of EGCG versus 
existing anxiety and mood disorder therapies. A greater number of studies with larger sample 
sizes, more inclusive populations, and a universal mood assessment would also prove beneficial.  
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